Search
Close
Search
Advanced Search
Search Menu
AI Discovery Assistant

Extract

Objective

To evaluate the efficacy and safety of Collagenase Clostridium Histolyticum (CCH) (Xiapex®) in the treatment of active Peyronie’s disease (PD) at a single centre.

Methods

This is a clinical audit of patients, with active Peyronie’s disease, who underwent CCH treatment at our center. Assessment of the angle of curvature was performed at baseline and 4 weeks after each treatment. Each treatment consisted of a single intralesional injection of CCH (0.9 mg), given in a fan-shaped manner, in the plaque around the point of maximum curvature. If needed, CCH injections were repeated at 4-week intervals. In between injections, patients used a combination of home manual plaque-modelling, a vacuum device and a penile-stretching device on a daily basis.

Results

To date, a total of 15 patients with active PD have completed CCH treatment and are under follow up. At baseline: the mean duration of PD was 5.3(1-10) months; PD pain was present in 9 patients; and the mean penile curvature was 49.5° (30°-80°). All but 1 patient had an improvement in curvature with a mean value of 26.5° (0°-42°) or 54.4% from baseline (0-75%). The end mean curvature was 23° (10°- 45°; p≤ 0.001). The mean number of CCH injections needed was 2.6 (1-8). 12 patients were completely satisfied with CCH treatment and will use traction therapy until PD stabilises, and 3 patients are moderately satisfied (2 of whom will have a plication surgery to deal with the residual curvature after PD stabilises). The single patient who did not achieve improvement in the dorsal curvature was also moderately satisfied as he had a lateral component of 30° which disappeared. As in stable disease, CCH in active PD was well tolerated by all patients with only mild and transient penile swelling and bruising occurring in all participants, but no systemic adverse events.

You do not currently have access to this article.
Download all slides